AI Imaging for Heart Procedures Gets $160M
Patients undergoing catheterization may one day benefit from AI-guided imaging, though the system is not yet approved.
Updated on Nov. 4, 2026 in Heart Disease
Laza Medical, a Shifamed portfolio company, announced up to $160 million in Series B financing led by GE HealthCare, with participation from Unorthodox Ventures, PA MedTech and AMED. The company is developing AI-powered robotic imaging for cardiac interventions, and its Laza Medical System is not yet approved for commercial sale anywhere.
Why it matters
Cardiovascular procedures are growing more complex, and care teams need more consistent image guidance as demand for specialized imaging expertise rises. The financing aims to support intelligent imaging for the cardiac catheterization lab, which is the setting where many heart procedures are performed.
The only clinical data cited is a first-in-human study at Oregon Health Sciences University Hospital, in which Dr. Firas Zahr used the software last year. The source does not report study size, outcomes or measured effects, so the evidence base remains preliminary.
The players
GE HealthCare
A medical technology company whose imaging and diagnostic equipment is widely used in cardiology and other clinical areas, and which led this round.
Laza Medical
A Shifamed portfolio company developing AI-powered robotic imaging systems for cardiac interventions, with its first system still in development.
Shifamed
A medical device company focused on cardiovascular devices, founded by serial entrepreneur Amr Salahieh, and the parent of Laza Medical.
Oregon Health Sciences University Hospital
A major academic medical center in Oregon that participated in the first-in-human clinical study of the Laza Medical software.
The details
The company combines artificial intelligence and robotics to simplify procedural imaging during cardiac interventions. Intelligent imaging of this kind is intended to give care teams more intuitive and consistent guidance during catheterization procedures. Company leadership says the approach should streamline workflows and reduce variability, with robotic-enabled procedures planned as a later step.
Timeline
Last year: Dr. Firas Zahr used the software in a first-in-human clinical study at Oregon Health Sciences University Hospital.
November 5, 2026: Laza Medical announced the up to $160 million Series B financing.
Health Landscape
Catheterization lab imaging is the guidance backbone for many coronary and structural heart procedures, and efforts to add automation aim to make that guidance more consistent. The Laza Medical System is still pre-approval, so its place in the standard of care has yet to be established.
If you have a heart condition that may require a catheterization procedure, the technology described here is not yet available, so your care today will not change because of this announcement. It is worth asking your cardiologist which imaging approaches your care team uses and what they consider when planning a procedure.
The takeaway
Advances in cardiac imaging are aimed at making procedures more consistent, but this system has not been approved and is still in development. If you are preparing for a heart procedure, discuss the imaging and care approach with your cardiologist.
Further reading
For broader context on the conditions these procedures treat, explore our Heart Disease coverage.
